Impel Pharmaceuticals Investor Relations Material
Latest events
Q1 2023
Impel Pharmaceuticals
Q3 2023
14 Nov, 2023
Q2 2023
18 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Impel Pharmaceuticals Inc
Access all reports
Impel Pharmaceuticals Inc is a biopharmaceutical company that develops intranasal drug delivery treatments for central nervous system disorders. The company’s delivery platform enables rapid and targeted administration of therapeutics for conditions such as migraines and Parkinson’s disease. It focuses on commercializing treatments through healthcare provider networks. Impel Pharmaceuticals Inc is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
IMPL
Country
🇺🇸 United States